CoChat

Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability

Open access
Moynihan, Kelly D., Holden, Rebecca L., Mehta, Naveen K., Wang, Chensu, Karver, Mark R., Dinter, Jens, Liang, Simon, Abraham, Wuhbet, Melo, Mariane B., Zhang, Angela Q., Li, Na, Gall, Sylvie Le, Pentelute, Bradley L., Irvine, Darrell J. · 2018 · Cancer Immunology Research
Cited by 83

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Antitumor T-cell responses have the potential to be curative in cancer patients, but the induction of potent T-cell immunity through vaccination remains a largely unmet goal of immunotherapy. We previously reported that the immunogenicity of peptide vaccines could be increased by maximizing delivery to lymph nodes (LNs), where T-cell responses are generated. This was achieved by conjugating the peptide to 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-PEG (DSPE-PEG) to promote albumin binding, which resulted in enhanced lymphatic drainage and improved T-cell responses. Here, we expanded upon these findings and mechanistically dissected the properties that contribute to the potency of this amphiphile-vaccine (amph-vaccine). We found that multiple linkage chemistries could be used to link peptides with DSPE-PEG, and further, that multiple albumin-binding moieties conjugated to peptide antigens enhanced LN accumulation and subsequent T-cell priming. In addition to enhancing lymphatic trafficking, DSPE-PEG conjugation increased the stability of peptides in serum. DSPE-PEG peptides trafficked beyond immediate draining LNs to reach distal nodes, with antigen presented for at least a week in vivo, whereas soluble peptide presentation quickly decayed. Responses to amph-vaccines were not altered in mice deficient in the albumin-binding neonatal Fc receptor (FcRn), but required Batf3-dependent dendritic cells (DCs). Amph-peptides were processed by human DCs equivalently to unmodified peptides. These data define design criteria for enhancing the immunogenicity of molecular vaccines to guide the design of next-generation peptide vaccines. Cancer Immunol Res; 6(9); 1025–38. ©2018 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-17-0607

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • An immunogenic personal neoantigen vaccine for patients with melanoma

    Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 2×

    “Trials where patients received personalized vaccines targeting predicted neoantigens have generated significant enthusiasm in the field because they demonstrate the feasibility of immunizing against antigens that should not be restrained by tolerance (3, 4).”
    Background
  • Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

    Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 2×

    “Peptide antigen sequences used are as follows: gp100EGP long, EGP20 (gp10020-39): AVGALEGPRNQDWLGVPRQL (18); gp100 EGP short, EGP9: EGPRNQDWL; E7 from HPV: RAHYNIVTF; SIV-gag AL11: AAVKNWMTQTL; the MHC II-restricted neoantigen MUT30: VDWENVSPELNSTDQ (3); OVA251-270: GLEQLESIINFEKLTEWTSS; and HIV gag p1764-93: LQPSLQTG…”
    Background
  • Batf3 Deficiency Reveals a Critical Role for CD8α + Dendritic Cells in Cytotoxic T Cell Immunity

    Hildner, K., Edelson, B. T., Purtha, W. E., Diamond, M., Matsushita, H., Kohyama, M., Calderon, B., Schraml, B. U., Unanue, E. R., Diamond, M. S., et al. (2008) · Science · doi:10.1126/science.1164206 · Cited by 2,081 · cited 18×

    “We tested the relative efficacy of several different albumin-binding moieties, the stability of amph-vaccine conjugates in the presence of serum proteases, the effect of using different adjuvants with amphpeptides, and the importance of the neonatal Fc receptor and cross-presenting dendritic cells (DCs) in amph-vaccin…”
    MethodInfluential
  • Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

    Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594 · cited 1×

    “For example, Ott and colleagues used "long" neoantigen-containing peptides as immunogens, which are attractive due to their defined nature, relative ease of manufacturing, favorable safety profile, and requirement of professional antigen presenting cells (APCs) for presentation (5).”
    Method

Show all 4 references

Cited by

See all 83

Metadata

Authors
Moynihan, K. D., Holden, R. L., Mehta, N. K., Wang, C., Karver, M. R., Dinter, J., Liang, S., Abraham, W., Melo, M. B., Zhang, A. Q., Li, N., Gall, S. L., Pentelute, B. L., & Irvine, D. J.
Venue
Cancer Immunology Research
Published
2018-09-01
Volume
6
Issue
9
Pages
1025-1038
ISSN
  • 2326-6066 (ISSN-L)
  • 2326-6074
OpenAlex
W2808820218
Cited by
83
References
4
FWCI
2.44
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. https://app.cochat.ai/papers/10.1158/2326-6066.cir-17-0607
The paper
Moynihan, K. D., Holden, R. L., Mehta, N. K., Wang, C., Karver, M. R., Dinter, J., Liang, S., Abraham, W., Melo, M. B., Zhang, A. Q., Li, N., Gall, S. L., Pentelute, B. L., & Irvine, D. J. (2018). Enhancement of Peptide Vaccine Immunogenicity by Increasing Lymphatic Drainage and Boosting Serum Stability. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-17-0607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.